Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Eun-Sun | - |
dc.contributor.author | Nam, Jeong-Seok | - |
dc.contributor.author | Jung, Ji-Youn | - |
dc.contributor.author | Cho, Nam-Pyo | - |
dc.contributor.author | Cho, Sung-Dae | - |
dc.date.available | 2020-02-28T15:44:33Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-11-24 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12106 | - |
dc.description.abstract | Cervical cancer is the third most common cancer and the third leading cause of death among women. However, the standard treatment for cervical cancer includes cisplatin, which can cause side effects such as hematological damage or renal toxicity. New innovations in cervical cancer treatment focus on developing more effective and better-tolerated therapies such as Sp1-targeting drugs. Previous studies suggested that mithramycin A (Mith) inhibits the growth of various cancers by decreasing Sp1 protein. However, how Sp1 protein is decreased by Mith is not clear. Few studies have investigated the regulation of Sp1 protein by proteasome-dependent degradation as a possible control mechanism for the regulation of Sp1 in cancer cells. Here, we show that Mith decreased Sp1 protein by inducing proteasome-dependent degradation, thereby suppressing cervical cancer growth through a DR5/caspase-8/Bid signaling pathway. We found that prolonged Mith treatment was well tolerated after systemic administration to mice carrying cervical cancer cells. Reduction of body weight was minimal, indicating that Mith was a good therapeutic candidate for treatment of cancers in which Sp1 is involved in promoting and developing disease. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.subject | TRANSCRIPTION FACTORS | - |
dc.subject | INDUCE APOPTOSIS | - |
dc.subject | DEATH RECEPTORS | - |
dc.subject | GROWTH-FACTOR | - |
dc.subject | CYTOCHROME-C | - |
dc.subject | FOLLOW-UP | - |
dc.subject | CELLS | - |
dc.subject | SP1 | - |
dc.subject | INHIBITION | - |
dc.subject | CARCINOMA | - |
dc.title | Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000346183900005 | - |
dc.identifier.doi | 10.1038/srep07162 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.4 | - |
dc.identifier.scopusid | 2-s2.0-84933686722 | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 4 | - |
dc.contributor.affiliatedAuthor | Nam, Jeong-Seok | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | TRANSCRIPTION FACTORS | - |
dc.subject.keywordPlus | INDUCE APOPTOSIS | - |
dc.subject.keywordPlus | DEATH RECEPTORS | - |
dc.subject.keywordPlus | GROWTH-FACTOR | - |
dc.subject.keywordPlus | CYTOCHROME-C | - |
dc.subject.keywordPlus | FOLLOW-UP | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | SP1 | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.